Schering's newco

Schering AG's decision to spin out its dermatology group could create one of the largest biotech companies in Europe. But to make it happen, the to-be-named company will need to bolster its clinical pipeline and expand its marketing capabilities.

Indeed, the new company is still in the process of being formed. Although he has yet to be appointed, Wolfgang Kehr told BioCentury that he will be CEO. Kehr is managing director of the center for dermatology at Schering (FSE:SCH; SHR, Berlin, Germany). ...